Rheumatoid arthritis
Adult: In combination with methotrexate for the treatment of moderate to severe cases: 3 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 3 mg/kg every 8 weeks thereafter. If response is incomplete, may consider adjusting the dose up to 10 mg/kg every 8 weeks; alternatively, the 3 mg/kg dose may be given as often as every 4 weeks. Doses are given via IV infusion over at least 2 hours. If signs and symptoms recur, re-administer treatment within 16 weeks following the last infusion. Dosage and treatment recommendations may vary among countries (refer to specific product guidelines).
Intravenous
Crohn's disease
Adult: For the treatment of moderate to severe cases with inadequate response to conventional therapy: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. If response is incomplete during maintenance treatment, may consider adjusting the dose up to 10 mg/kg. Alternatively, an initial 5 mg/kg dose may be followed by repeat 5 mg/kg infusions when signs and symptoms of the disease recur. Re-administration of treatment when signs and symptoms recur may be done within 16 weeks following the last infusion. Doses are given via IV infusion over at least 2 hours. Dosage recommendations may vary among countries (refer to specific product guidelines).
Child: 6-17 years For the treatment of moderate to severe cases in patients who have an inadequate response to conventional therapy or for patients who are intolerant to or have contraindications for such therapy: In combination with immunosuppressive therapy: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. Doses are given via IV infusion over at least 2 hours. Dosage and treatment recommendations may vary among countries (refer to specific product guidelines).
Child: 6-17 years For the treatment of moderate to severe cases in patients who have an inadequate response to conventional therapy or for patients who are intolerant to or have contraindications for such therapy: In combination with immunosuppressive therapy: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. Doses are given via IV infusion over at least 2 hours. Dosage and treatment recommendations may vary among countries (refer to specific product guidelines).
Intravenous
Ulcerative colitis
Adult: For the treatment of moderate to severe cases with inadequate response to conventional therapy: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. Doses are given via IV infusion over at least 2 hours. Treatment recommendations may vary among countries (refer to specific product guidelines).
Child: 6-17 years For the treatment of moderate to severe cases with inadequate response to conventional therapy, or for severe cases who are intolerant to or have contraindications for conventional therapy: Same as adult dose.
Child: 6-17 years For the treatment of moderate to severe cases with inadequate response to conventional therapy, or for severe cases who are intolerant to or have contraindications for conventional therapy: Same as adult dose.
Intravenous
Fistulising Crohn's disease
Adult: To reduce the number of draining enterocutaneous and rectovaginal fistulae and maintain fistula closure: 5 mg/kg at weeks 0, 2, and 6. If response is inadequate after the 3 doses, no additional treatment should be given. In responding patients, give a maintenance dose of 5 mg/kg every 8 weeks. If signs and symptoms recur, re-administer 5 mg/kg followed by 5 mg/kg every 8 weeks. Re-administration of treatment may be done within 16 weeks following the last infusion. Doses are given via IV infusion over at least 2 hours.
Intravenous
Ankylosing spondylitis
Adult: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 6-8 weeks thereafter. Doses are given via IV infusion over at least 2 hours. Treatment recommendations may vary among countries (refer to specific product guidelines).
Intravenous
Psoriatic arthritis
Adult: As monotherapy or in combination with methotrexate: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. Doses are given via IV infusion over at least 2 hours. Treatment recommendations may vary among countries (refer to specific product guidelines).
Intravenous
Plaque psoriasis
Adult: For the treatment of moderate to severe cases unresponsive to, or who are intolerant or have a contraindication to other systemic therapy: 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks thereafter. If there is no response after 14 weeks (4 doses), no additional treatment should be given. Doses are given via IV infusion over at least 2 hours. Treatment recommendations may vary among countries (refer to specific product guidelines).